Cytokinetics (CYTK) Trading Down 0% After Earnings Miss

Cytokinetics, Inc. (NASDAQ:CYTK)’s share price dropped 0% during trading on Friday following a dissappointing earnings announcement. The stock traded as low as $7.50 and last traded at $8.02. Approximately 785,805 shares were traded during trading, an increase of 117% from the average daily volume of 362,521 shares. The stock had previously closed at $8.02.

The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by ($0.04). The firm had revenue of ($0.02) million for the quarter, compared to the consensus estimate of $4.83 million. Cytokinetics had a negative net margin of 172.27% and a negative return on equity of 62.64%.

CYTK has been the topic of several research reports. TheStreet cut Cytokinetics from a “c” rating to a “d” rating in a research report on Friday, October 27th. JMP Securities reaffirmed an “outperform” rating and set a $13.00 price objective (down from $17.00) on shares of Cytokinetics in a research report on Tuesday, November 21st. They noted that the move was a valuation call. Cantor Fitzgerald cut Cytokinetics from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $21.00 to $10.00 in a research report on Wednesday, November 22nd. Needham & Company LLC cut Cytokinetics from a “strong-buy” rating to a “buy” rating and cut their price objective for the company from $22.00 to $12.00 in a research report on Tuesday, November 21st. Finally, ValuEngine cut Cytokinetics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $17.91.

Institutional investors and hedge funds have recently modified their holdings of the company. Birchview Capital LP bought a new stake in shares of Cytokinetics in the 3rd quarter worth approximately $145,000. Piedmont Investment Advisors LLC bought a new stake in shares of Cytokinetics in the 3rd quarter worth approximately $159,000. GSA Capital Partners LLP bought a new stake in shares of Cytokinetics in the 3rd quarter worth approximately $187,000. Virtu Financial LLC bought a new stake in shares of Cytokinetics in the 4th quarter worth approximately $112,000. Finally, Teacher Retirement System of Texas bought a new stake in shares of Cytokinetics in the 4th quarter worth approximately $113,000. 74.06% of the stock is currently owned by hedge funds and other institutional investors.

The company has a quick ratio of 7.60, a current ratio of 7.60 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $432.42, a PE ratio of -3.11 and a beta of 1.03.

COPYRIGHT VIOLATION NOTICE: This article was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://stocknewstimes.com/2018/02/16/cytokinetics-cytk-trading-down-0-after-earnings-miss.html.

About Cytokinetics

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply